Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

GEM20110714 (ClinicalTrials.gov identifier: NCT01528618), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement with gemcitabine plus cisplatin (GP) versus fluorouracil plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Shaodong, Zhang, Yaxiong, Yu, Gengsheng, Peng, Peijian, Peng, Jiewen, Jia, Jun, Wu, Xuan, Huang, Yan, Yang, Yunpeng, Lin, Qing, Xi, Xuping, Xu, Mingjun, Chen, Dongping, Lu, Xiaojun, Wang, Rensheng, Cao, Xiaolong, Chen, Xiaozhong, Lin, Zhixiong, Xiong, Jianping, Lin, Qin, Xie, Conghua, Li, Zhihua, Pan, Jianji, Li, Jingao, Wu, Shixiu, Lian, Yingni, Yang, Quanlie, Zhao, Chong, Fang, Wenfeng, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500603/
https://www.ncbi.nlm.nih.gov/pubmed/34379443
http://dx.doi.org/10.1200/JCO.21.00396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500603/
https://www.ncbi.nlm.nih.gov/pubmed/34379443
http://dx.doi.org/10.1200/JCO.21.00396

Ejemplares similares